IM Cannabis (IMCC) Non Operating Interest Expenses (2020 - 2024)
IM Cannabis (IMCC) posted quarterly Non Operating Interest Expenses of -$361409.1 for Q1 2024, up 38.54% year-over-year from -$260866.1 in Q2 2023, and up 77.04% quarter-over-quarter from -$1.6 million in Q2 2023.
IM Cannabis (IMCC) Non Operating Interest Expenses (2020 - 2024) Analysis & Trends
IM Cannabis' Non Operating Interest Expenses history runs 5 years deep, the most recent figure standing at -$361409.1 for Q1 2024.
- In Q1 2024, Non Operating Interest Expenses rose 38.54% year-over-year to -$361409.1; the TTM figure through Mar 2024 stood at -$4.2 million (down 27.48% YoY), while the FY2019 annual figure was $986023.1, changed N/A from the prior year.
- Non Operating Interest Expenses for Q1 2024 stood at -$361409.1, up from -$1.6 million in the prior quarter.
- The five-year high for Non Operating Interest Expenses was $890002.5 in Q3 2020, with the low at -$5.1 million in Q2 2020.
- The 5-year median for Non Operating Interest Expenses is -$441745.2 (2021), against an average of -$958399.4.
- The sharpest annual moves came in 2021 and 2022: Non Operating Interest Expenses soared 91.35% in 2021, then slumped 339.59% in 2022.
- IM Cannabis' Non Operating Interest Expenses stood at $890002.5 in 2020, then plunged by 96.34% to $32570.8 in 2021, then plunged by 5390.62% to -$1.7 million in 2022, then advanced by 8.67% to -$1.6 million in 2023, then jumped by 77.04% to -$361409.1 in 2024.
- Business Quant data shows IMCC's Non Operating Interest Expenses at -$361409.1 in Q1 2024, -$1.6 million in Q2 2023, and -$588058.6 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -400.56 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 2.90 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 120.70 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 2.90 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | IM Cannabis | 549,631.99 | -619,338.18 | 1.09 Mn | 2.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -361,409.13 |
| Jun 30, 2023 | -1.57 Mn |
| Mar 31, 2023 | -588,058.61 |
| Jun 30, 2022 | -1.72 Mn |
| Mar 31, 2022 | -1.05 Mn |
| Sep 30, 2021 | 32,570.78 |
| Jun 30, 2021 | -441,745.25 |
| Mar 31, 2021 | -239,400.03 |
| Sep 30, 2020 | 890,002.47 |
| Jun 30, 2020 | -5.11 Mn |
| Mar 31, 2020 | -378,168.56 |